Welcome to our dedicated page for HeartSciences news (Ticker: HSCS), a resource for investors and traders seeking the latest updates and insights on HeartSciences stock.
HeartSciences Inc. (NASDAQ: HSCS) is a healthcare information technology and medical technology company focused on advancing ECG/EKG diagnostics through artificial intelligence. News related to HeartSciences often centers on the development and commercialization of its MyoVista Insights™ cloud‑native ECG management platform and its MyoVista® wavECG™ device, both designed to integrate AI‑ECG algorithms into clinical workflows.
Investors and healthcare professionals following HSCS news can find updates on regulatory milestones, such as the company’s submission of the MyoVista wavECG device to the U.S. Food and Drug Administration for 510(k) premarket clearance and the FDA Breakthrough Device designation granted for its aortic stenosis ECG algorithm. Company announcements also cover product enhancements, including new versions of the MyoVista Insights platform aimed at improving usability, workflow efficiency, interoperability with multiple ECG devices, and integration with hospital EHR systems.
HeartSciences’ news flow includes business updates on early adopter deployments of MyoVista Insights, commercial agreements for its AI‑ECG platform, and information about its intellectual property portfolio, including patents related to AI‑ECG algorithms and estimation of echocardiographic parameters from ECG data. Financial news items provide context on the company’s reported results and capital initiatives, as disclosed in its public filings and press releases.
By monitoring HSCS news, readers can track developments in HeartSciences’ AI‑ECG algorithms, progress in its cloud‑based ECG management solutions, and key regulatory and commercial milestones that the company reports as it works to enhance the clinical utility of ECGs in frontline and point‑of‑care cardiac screening.
HeartSciences (NASDAQ: HSCS) reported its fiscal 2025 results and business updates, highlighting significant progress in AI-powered ECG technology. The company's flagship MyoVista Insights™ cloud-native software platform launched in May 2025, designed to modernize ECG management systems and serve as a marketplace for AI-ECG algorithms.
Key developments include: CMS approval for AI-ECG algorithm reimbursement at $128 per test, FDA Breakthrough Device designation for their aortic stenosis algorithm, and expansion to 44 granted patents worldwide. The company is preparing for FDA 510(k) submission of its MyoVista wavECG™ device and targets FDA submission of its first cloud-based algorithm for detecting reduced ejection fraction in early 2026.
Financially, HeartSciences reported $1.1 million in cash as of April 30, 2025, and subsequently raised $3.1 million through a Reg A+ offering and converted $0.9 million of debt to equity.
HeartSciences (NASDAQ: HSCS) has secured its first commercial customer, Westcliffe Health Innovations in the UK, for its MyoVista Insights™ platform. This cloud-native ECG management system is designed to be the first vendor- and device-agnostic platform capable of running AI-ECG algorithm models from multiple partners. The implementation will serve as a key reference site within the UK market, particularly for the National Health Service (NHS).
Westcliffe Health Innovations, led by Dr. Matthew Fay, provides cardiology services to the NHS in the Bradford and Leeds region. The partnership aims to enhance clinical decision-making and improve healthcare IT efficiency by streamlining ECG workflows and reducing operational costs. This milestone follows the recent launch of MyoVista Insights and its early adopter program earlier this month.
HeartSciences (Nasdaq: HSCS) announced that CEO Andrew Simpson will present at the Emerging Growth Conference 82 on Wednesday, May 21, 2025 at 10:15 AM EDT. The virtual presentation will include a live Q&A session, providing investors insight into the company's AI-ECG platform and mission.
HeartSciences specializes in AI-powered medical technology focused on transforming ECGs/EKGs for earlier heart disease detection. The presentation will highlight their AI-ECG platform, designed to enhance standard ECG diagnostic capabilities at the point of care. Simpson will also discuss a current Regulation A investment opportunity available to qualified investors.
HeartSciences (Nasdaq: HSCS) has announced an upcoming investor webinar scheduled for Wednesday, May 14, 2025, at 2:00 p.m. EDT. The event will feature CEO Andrew Simpson who will present and conduct a Q&A session focusing on the company's AI-powered ECG/EKG technology platform. The webinar will provide insights into HeartSciences' mission to transform early heart disease detection and its market opportunities. Simpson will also discuss a Regulation A investment opportunity available to qualified investors.
HeartSciences (NASDAQ: HSCS) has launched its MyoVista Insights™ platform, a cloud-native ECG Management System designed to enhance clinical decision-making and healthcare IT efficiency. The platform features vendor-agnostic integration capabilities for AI-ECG algorithms, a unique prioritization system, and standardized ECG reporting protocols.
Key features include patient-centric longitudinal comparisons, disease progression tracking, and enhanced workflow efficiency. Built on AWS technology stack, MyoVista Insights offers a pay-as-you-go model, reducing implementation and storage costs compared to legacy systems. The platform will integrate both company-developed and third-party AI-ECG algorithms in future releases to help identify patients requiring further cardiac testing earlier.
HeartSciences (HSCS) reported Q3 FY2025 financial results and business updates, highlighting significant progress in AI-powered ECG technology. The company reported no revenues for Q3 FY2025, with cash and cash equivalents of $2.6 million and shareholders' equity of $1.8 million as of January 31, 2025.
Key developments include:
- Final pre-submission meeting with FDA for MyoVista wavECG device in February 2025, with expected FDA clearance submission in H1 2025
- Successful completion of Phase 1 MyoVista Insights cloud-native platform in December 2024
- Pre-validation work completed with Rutgers for low ejection fraction algorithm
- CMS 2025 OPPS final rule inclusion enabling reimbursement upon commercial launch
The company's strategy focuses on modernizing ECG technology through AI-enhanced hardware and software solutions, positioning itself as the only company building next-gen ECG device hardware, device-agnostic cloud-native software, and AI-ECG algorithms.
HeartSciences (Nasdaq: HSCS), an AI-powered medical technology company focused on transforming ECGs/EKGs for earlier heart disease detection, has announced its engagement with Integrous Communications to enhance investor relations. The partnership aims to develop and execute a comprehensive investor communications program, leveraging Integrous' expertise in working with leading medical companies.
Andrew Simpson, Chairman and CEO, emphasized the importance of maintaining robust investor communications as the company continues its mission of transforming cardiovascular screening through AI-ECG technology. Mark Komonoski, Partner of Integrous Communications, expressed enthusiasm about partnering with HeartSciences to communicate its growth strategy and value proposition to the investment community.